Neoadjuvant endocrine therapy in breast cancer
- VernacularTitle:乳腺癌新辅助内分泌治疗
- Author:
Bin ZHANG
- Publication Type:Journal Article
- Keywords:
breast cancer;
postmenopausal;
ER;
neoadjuvant therapy;
3rd generation AI;
tamoxifen
- From:
China Oncology
2006;0(09):-
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant chemotherapy is standard care of locally advanced primary breast cancer, but it is more difficult to treat elderly women with locally advanced breast cancer who cannot tolerate the toxicities of chemotherapy. According to the literature, neoadjuvant endocrine therapy seems to be effective and well tolerated. The clinical data (overall response rates, conservative surgery rates) on 3rd generation aromatase inhibitors appears to be better than tamoxifen. Neoadjuvant endocrine therapy could be a reasonable alternative to chemotherapy for postmenopausal women with ER-positive and/or PgR-positive breast cancer.
